Jane Street’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-83,933
| Closed | -$367K | – | 11405 |
|
|
2025
Q4 | $404K | Sell |
83,933
-216,522
| -72% | -$974K | ﹤0.01% | 8172 |
|
|
2025
Q3 | $1.36M | Buy |
300,455
+77,659
| +35% | +$285K | ﹤0.01% | 5671 |
|
|
2025
Q2 | $688K | Sell |
222,796
-57,964
| -21% | -$192K | ﹤0.01% | 6334 |
|
|
2025
Q1 | $980K | Buy |
+280,760
| New | +$936K | ﹤0.01% | 5610 |
|
|
2024
Q4 | – | Sell |
-66,910
| Closed | -$258K | – | 9268 |
|
|
2024
Q3 | $258K | Sell |
66,910
-136,488
| -67% | -$524K | ﹤0.01% | 8277 |
|
|
2024
Q2 | $629K | Buy |
203,398
+159,279
| +361% | +$478K | ﹤0.01% | 6652 |
|
|
2024
Q1 | $114K | Sell |
44,119
-52,390
| -54% | -$136K | ﹤0.01% | 8482 |
|
|
2023
Q4 | $241K | Buy |
+96,509
| New | +$189K | ﹤0.01% | 7951 |
|
|
2023
Q2 | – | Sell |
-136,288
| Closed | -$413K | – | 8584 |
|
|
2023
Q1 | $413K | Buy |
136,288
+29,742
| +28% | +$83.9K | ﹤0.01% | 6652 |
|
|
2022
Q4 | $248K | Buy |
106,546
+87,677
| +465% | +$210K | ﹤0.01% | 7333 |
|
|
2022
Q3 | $36K | Sell |
18,869
-23,732
| -56% | -$55.9K | ﹤0.01% | 9041 |
|
|
2022
Q2 | $115K | Sell |
42,601
-39,213
| -48% | -$100K | ﹤0.01% | 8552 |
|
|
2022
Q1 | $244K | Sell |
81,814
-271,066
| -77% | -$830K | ﹤0.01% | 8722 |
|
|
2021
Q4 | $1.37M | Buy |
352,880
+130,119
| +58% | +$505K | ﹤0.01% | 5267 |
|
|
2021
Q3 | $956K | Buy |
222,761
+201,526
| +949% | +$672K | ﹤0.01% | 5989 |
|
|
2021
Q2 | $65K | Sell |
21,235
-32,127
| -60% | -$99.5K | ﹤0.01% | 9431 |
|
|
2021
Q1 | $177K | Buy |
53,362
+14,298
| +37% | +$55.2K | ﹤0.01% | 8347 |
|
|
2020
Q4 | $139K | Buy |
39,064
+22,239
| +132% | +$77.9K | ﹤0.01% | 7102 |
|
|
2020
Q3 | $53K | Sell |
16,825
-89,356
| -84% | -$272K | ﹤0.01% | 6904 |
|
|
2020
Q2 | $194K | Buy |
106,181
+33,256
| +46% | +$54.4K | ﹤0.01% | 6390 |
|
|
2020
Q1 | $73K | Buy |
+72,925
| New | +$197K | ﹤0.01% | 5025 |
|
|
2019
Q3 | – | Sell |
-167,188
| Closed | -$348K | – | 4988 |
|
|
2019
Q2 | $348K | Buy |
+167,188
| New | +$428K | ﹤0.01% | 4020 |
|
|
2017
Q4 | – | Sell |
-10,983
| Closed | -$68K | – | 4490 |
|
|
2017
Q3 | $68K | Buy |
+10,983
| New | +$47K | ﹤0.01% | 4312 |
|
|
2015
Q4 | – | Sell |
-25,374
| Closed | -$155K | – | 3927 |
|
|
2015
Q3 | $155K | Buy |
+25,374
| New | +$225K | ﹤0.01% | 3274 |
|
|
2015
Q2 | – | Sell |
-10,200
| Closed | -$178K | – | 3577 |
|
|
2015
Q1 | $178K | Buy |
+10,200
| New | +$209K | ﹤0.01% | 2927 |
|
|
2014
Q4 | – | Sell |
-54,179
| Closed | -$1.15M | – | 2419 |
|
|
2014
Q3 | $1.15M | Buy |
+54,179
| New | +$885K | 0.01% | 851 |
|
|
2014
Q2 | – | Sell |
-21,400
| Closed | -$460K | – | 2492 |
|
|
2014
Q1 | $460K | Buy |
+21,400
| New | +$385K | 0.01% | 1642 |
|
Other funds holding ABUS
TSC
WCM
VCM
RCMNY
ACM
Jane Street's ABUS Position: Q1 2026 in Review
Jane Street sold out of Arbutus Biopharma (ABUS) in Q1 2026, closing a stake of 83,933 shares — an estimated $367K sold.
Jane Street first reported a position in ABUS in Q1 2014 and held it in 27 quarters. The position peaked at $1.37M in Q4 2021. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.
- Jane Street reported no remaining Arbutus Biopharma position as of Q1 2026 after selling out during the quarter.
- Jane Street sold 83,933 Arbutus Biopharma shares in Q1 2026, an estimated $367K.
- Jane Street first reported a position in Arbutus Biopharma in Q1 2014 and held it in 27 quarters.
- Jane Street's Arbutus Biopharma position peaked at $1.37M in Q4 2021.
- 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.